A phase I clinical trial on 42 patients with relapsed/refractory MM who received at least three prior lines of therapy administered TRAC + CD52 KO anti-BCMA (B cell maturation antigen) to enable allogeneic CAR Ts who are able to tolerate alemtuzumab plus FC lymphodepletion. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.